Bosley will initially offer FoLix in its Beverly Hills locations starting in September 2024, gradually expanding the service to other locations across the country. The partnership marks a new era of hair loss treatment by introducing the first FDA-cleared fractional laser hair removal solution to U.S. customers for the first time, potentially benefiting more than 80 million people suffering from hair loss in the country.1 The partnership also highlights Bosley’s dedication to helping customers in the fight against hair loss, strengthening its position as the world’s most trusted and experienced hair restoration experts.
“As we remain at the forefront of innovation and excellence, we are always seeking out the latest and most effective advancements to support our clients on their hair restoration journey,” said Rob Spurrell, CEO and President of Bosley. “FoLix is a powerful and perfect fit within our expanding range of solutions, as its non-surgical, in-clinic approach minimizes discomfort and shows promising results in just a few monthly sessions.”
“At Bosley, we understand that hair loss can have a significant impact on our patients’ lives. For 50 years, we have been using new technologies to help patients suffering from hair loss both surgically and non-surgically, and we are excited to introduce Lumenis Follicles treatment, an innovative treatment designed to help patients regain their hair and their confidence,” said Ken Washenick, MD, chief medical officer at Bosley.
After receiving FDA clearance earlier this year, Luminous launched FoLix, a groundbreaking innovation and first of its kind in hair loss treatment. Developed with Luminous’ proprietary technology, FoLix offers a solution that is non-invasive, effective, simple and safe. The solution uses a unique approach to deliver precise pulses of laser light, harnessing the body’s natural processes to stimulate hair follicles. FoLix is expected to generate significant interest from those struggling with hair loss as it requires no chemicals, needles, anesthesia or downtime and delivers results in just four to six monthly sessions.
Luminous and Bosley are committed to raising awareness and educating people about the causes, prevention and treatment of hair loss. Hair loss is a common condition that can manifest at different stages in life, with two in three men experiencing hair loss by age 35 and one in two women experiencing hair loss by age 50. The introduction of FoLix fills this strong clinical need and can have a profound impact on people’s self-esteem, confidence and quality of life.
“The results demonstrated in Luminous’ preclinical and clinical studies make FoLix a major step forward in the world of hair restoration for both patients and healthcare providers,” said Brad Oliver, president of Luminous Americas. “Our partnership with Bosley marks an exciting first step in bringing FoLix to the U.S. market, and we are confident that this innovative technology will make a real difference in the lives of millions of people affected by hair loss, empowering them to take control of their daily experience and feel more confident.”
To learn more about FoLix™, visit Lumenis.com/FoLix.
About Luminous
Lumenis is a global leader in the medical aesthetic market and a world-renowned expert in the development and commercialization of innovative energy-based technologies such as Laser, Intense Pulsed Light (IPL) and Radiofrequency (RF). For over 50 years, Lumenis’ breakthrough products have redefined medical care, setting technological and clinical gold standards, revolutionizing existing treatments and creating solutions for previously untreatable conditions. Lumenis is a portfolio company of EQT Private Capital Asia. To learn more about Lumenis clinical solutions, please visit www.lumenis.com.
About Bosley
Founded in 1974, Bosley is the largest hair restoration clinic in the United States. For over 50 years, Bosley physicians have been dedicated to the art and science of hair restoration for both men and women, using innovative, artistic and scientific techniques. With over 500,000 hair restoration procedures performed (with patients in all 50 states and over 60 countries), Bosley has helped hundreds of thousands of patients find a permanent solution to their hair loss. For more information, visit www.bosley.com.
About FoLix™
FoLix™ is a non-ablative fractional laser device intended to improve the appearance of scalp hair in adult men and women with Fitzpatrick skin types I to IV who wish to treat alopecia.
FoLix™ treatment may result in redness, swelling, scarring, and pigmentation changes. Use of FoLix is contraindicated in patients with a history of skin cancer, active infection, fungal disease, or bacterial disease. For a complete list of contraindications and risks, please refer to the system’s user manual.
Media Contact
Andrew Spivak, (email protected).
Courtney Myers (email protected).
1 According to the American Academy of Dermatology.
2 According to the American Academy of Dermatology.
3 According to NIH’s MedlinePlus.
PB-00081710 Rev. A
SOURCE Lumenis Be. Ltd.
